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Abstract
Background: Circadian oscillation of clock-controlled gene expression is mainly regulated at the
transcriptional level. Heterodimers of CLOCK and BMAL1 act as activators of target gene
transcription; however, interactions of PER and CRY proteins with the heterodimer abolish its
transcriptional activation capacity. PER and CRY are therefore referred to as negative regulators
of the circadian clock. To further elucidate the mechanism how positive and negative components
of the clock interplay, we characterized the interactions of PER2, CRY1 and CRY2 with BMAL1
and CLOCK using a mammalian two-hybrid system and co-immunoprecipitation assays.
Results: Both PER2 and the CRY proteins were found to interact with BMAL1 whereas only PER2
interacts with CLOCK. CRY proteins seem to have a higher affinity to BMAL1 than PER2.
Moreover, we provide evidence that PER2, CRY1 and CRY2 bind to different domains in the
BMAL1 protein.
Conclusion: The regulators of clock-controlled transcription PER2, CRY1 and CRY2 differ in
their capacity to interact with each single component of the BMAL1-CLOCK heterodimer and, in
the case of BMAL1, also in their interaction sites. Our data supports the hypothesis that CRY
proteins, especially CRY1, are stronger repressors than PER proteins.
Background
Circadian rhythms are recurring fluctuations with a period
of about 24 hours that can be observed in the physiology
and behavior of most living organisms from cyanobacte-
ria to humans [1]. They are controlled by an autonomous
circadian clock, which can be synchronized to the envi-
ronmental day-night cycle. In mammals, the suprachias-
matic nucleus (SCN), a structure in the ventral part of the
hypothalamus, appears to be the main coordinator of the
circadian timing system [2,3] synchronizing peripheral
clocks present in all tissues throughout the body [4].
The oscillatory mechanism underlying the circadian clock
has been unraveled by means of genetic analysis in Dro-
sophila and mammals [5]. In the latter, a heterodimeric
complex of two transcriptional activators, CLOCK and
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promoters of target genes and thereby activates the expres-
sion of three Period (Per1, Per2 and Per3) and two Crypto-
chrome genes (Cry1 and Cry2). PER and CRY proteins
translocate to the nucleus where CRY proteins act as
potent (and PER proteins as mild) inhibitors of CLOCK-
BMAL1-induced transcription [6,7]. The positive
(CLOCK-BMAL1) and negative (CRY, PER) arms of the
feedback loop are coupled via the nuclear orphan receptor
REV-ERBα [8] generating a stabilized feedback loop that
drives recurrent rhythms in mRNA and protein levels of
clock components.
Transcriptional reporter assays, yeast two-hybrid screens
and co-immunoprecipitation experiments have been suc-
cessfully used to identify molecular interactions of clock
components at the protein level [6,7,9-12]. Interactions of
BMAL1 with CLOCK, NPAS2, DEC1 and DEC2 have been
identified. Furthermore it has been suggested that the
transactivation activity of BMAL1 is mediated by interac-
tion with CREB binding protein (CBP) or p300 [13].
Many different approaches have been employed to char-
acterize the interactions between the repressors PER2,
CRY1 and CRY2 and the BMAL1-CLOCK heterodimer,
but still the picture is far from being clear. It is thought
that CRY1 plays a key role in repressing the transcriptional
activation potential of the heterodimer, and recently, var-
ious attempts have been made to elucidate the mecha-
nism by which interaction of CRY1 with BMAL1 and/or
CLOCK inhibits transcription [14-17]. However, many of
these studies use multimeric protein complexes, which do
not always satisfactorily identify the exact interactions
between two individual components of the complex.
We decided to choose a complementary approach and to
investigate the interactions of PER2, CRY1 and CRY2 with
BMAL1 and CLOCK using a mammalian two-hybrid sys-
tem where we only overexpressed two of the components
– one part of the activating heterodimer and one repressor
– at a time. All interactions identified in the two-hybrid
system were confirmed by co-immunoprecipitation. Our
results indicate that in our conditions, CRY1, CRY2 and
PER2 proteins interact with BMAL1 by binding to differ-
ent sites of BMAL1, but that only PER2 interacts with
CLOCK alone. Moreover, in keeping with the idea that the
CRY proteins are more potent inhibitors than PER2, we
found that CRY1 and CRY2 both modify the interaction
between PER2 and BMAL1, but not vice versa.
Results and Discussion
Interaction of PER2, CRY1 and CRY2 with BMAL1
We first sought to identify the interactions between each
of the repressors with BMAL1 using a mammalian two-
hybrid system. HER911 cells were co-transfected with
Bmal1 fused to the Gal4 DNA binding domain (Gal4
DBD) and either Per2, Cry1 or Cry2 fused to the activation
domain of the viral protein VP16. In this system, an inter-
action of the two clock components reconstitutes a func-
tional transcription factor that will activate a luciferase
reporter under the control of a GAL4-based promoter. For
GAL4-BMAL1/PER2-VP16, a 1000-fold increase in luci-
ferase activity was observed (Fig. 1A). Similar values were
obtained for GAL4-BMAL1/CRY1-VP16 and GAL4-
BMAL1/CRY2-VP16 (750- and 950-fold, respectively; Fig.
1C). However, only a minimal activation of the reporter
was seen when GAL4-BMAL1 was expressed alone or
together with an unrelated fusion protein (PAX5-VP16) or
when the VP16 fusions were co-transfected with the Gal4
DBD alone (Fig. 1A, C).
Both PER2 (Fig. 1B) and the CRY proteins (Fig. 1D, E)
could be co-immunoprecipitated from extracts of
HER911 cells co-transfected with Bmal1-GFP and the
respective interaction partner using an anti-GFP antibody.
We therefore conclude that all three proteins are able to
bind to BMAL1, which is in line with previous reports
[6,15,18,19]. The fact that each of the three repressors can
interact with BMAL1 and thus has the potential to influ-
ence BMAL1-CLOCK mediated transcription would also
explain why Per2, Cry1 and Cry2 mutant mice all display
an altered expression of genes regulated by BMAL1 and
CLOCK [18,20-22].
Interactions with CLOCK
When repeating the same experiments using Gal4-Clock
instead of Gal4-Bmal1, we still found a 75-fold transacti-
vation of the reporter in the case of co-transfection with
Per2 (Fig. 2A). However, co-transfection with Cry1/2-
VP16 did not induce luciferase more than transfection
with Gal4-Clock alone (Fig. 2C). Using an anti-HA anti-
body, were we able to co-immunoprecipitate PER2 from
extracts of cells co-transfected with Per2 and HA-tagged
Clock (Fig. 2B). Our results hint at a binding of PER2, but
not CRY1 or CRY2, to CLOCK. PER2-CLOCK interactions
have been observed in the SCN and piriform cortex as
well [23].
CRY, especially CRY1, binding to BMAL1 has been
described many times in various systems. For CRY bind-
ing to CLOCK, however, contradictory findings have been
published. Griffin et al. do not observe clear interactions
between CRY1/2 and CLOCK in a yeast two-hybrid system
[6], whereas Shearman et al. do [18]. Kiyohara et al. [15]
report that they were not able to co-immunoprecipitate
CLOCK with CRY1 in the absence of BMAL1, and also in
other cases BMAL1/CLOCK(/PER2)/CRY1 complexes,
rather than individual components, have been used to
characterize interactions [17,24]. In the SCN and the piri-
form cortex, though, CRY1 co-immunoprecipitated withPage 2 of 16
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CRY1 binding to CLOCK in co-transfected HeLa cells.
Therefore, it appears likely that in this case the respective
results depend strongly on the system and cell type used
and that cell-specific factors might be involved in mediat-
ing the interaction. In the mammalian two-hybrid system
we employed in HER911 cells, CRY1 and 2 do not interact
with CLOCK.
CRY1 and CRY2 influence the interaction between PER2 
and BMAL1
Since in our system, all three repressors bind to BMAL1,
we wanted to know whether these proteins mutually
influence each other's binding to BMAL1. We first ana-
lyzed the influence of CRY1 and 2 on the interaction
between PER2 and BMAL1. HER911 cells were co-trans-
fected with Gal4-Bmal1, Per2-VP16 and different amounts
PER2, CRY1 and CRY2 all interact with BMAL1Figure 1
PER2, CRY1 and CRY2 all interact with BMAL1. (A) and (C) HER911 cells were co-transfected with 3 μg pFR-luc, 0.1 μg 
pCMV-lacZ and the indicated expresssion plasmids. For each experiment (n = 6), values obtained for cells transfected with the 
luciferase reporter alone were set to 1. *** p < 0.001 as determined by student's t-test compared to all other columns. (B), (D) 
and (E) HER911 cells were co-transfected with pSCT1-Bmal1-GFP and pSCT1-Per2 (B), pSTC-TK-Cry1 (D) or pSTC-TK-Cry2 (E). 
Total cell extracts (left panels) or immunoprecipitates using an anti-GFP antibody (right panels) were subjected to Western 
blotting using antibodies against PER2, CRY1 and CRY2, respectively. Blots are representative results from one experiment, all 
co-immunoprecipitations were repeated twice. WB Western Blot, IP immunoprecipitation.Page 3 of 16
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observed only a very slight increase in reporter luciferase
activity when low amounts (1–3 ng) of the plasmid were
co-transfected, starting from 100 ng luciferase activity
decreased markedly (Fig. 3A, open squares). When we co-
transfected Cry2, however, the increase in reporter activity
was markedly higher and sustained over a much wider
dose range (1–100 ng), a decrease was observed only with
the two highest amounts of co-transfected plasmid (Fig.
3A, open triangles).
Our results indicate that CRY1 and CRY2 have different
effects on PER2-BMAL1 interaction. We wished to find out
whether this would still be true in the presence of CLOCK
and repeated the co-transfections as described above, but
additionally co-transfected Clock. We observed an overall
higher reporter activity but were able to reproduce the dif-
ferences between Cry1 (Fig. 3A, solid squares) and Cry2
(Fig. 3A, solid triangles). A two-way ANOVA analysis of
the data showed highly significant differences between
Cry1 and Cry2 (p < 0.001), a highly significant dose-
dependence (p < 0.001) and an equally highly significant
interaction between the two parameters (p < 0.001).
To exclude that the modulations of reporter activity were
only due to an increase or decrease in GAL4-BMAL1 or
PER2-VP16 expression, we analyzed the total expression
levels of the two proteins by Western blot. Co-transfection
of 1 ng-1 μg Cry1 expression plasmid led to a dose-
dependent increase in PER2-VP16 expression whereas it
did not influence GAL4-BMAL1 levels, co-transfection of
Cry2 caused a slight increase in both PER2-VP16 and
Only PER2, but neither CRY1 nor CRY2, interacts with CLOCKFigure 2
Only PER2, but neither CRY1 nor CRY2, interacts with CLOCK. (A) and (C) HER911 cells were co-transfected with 
pFR-luc, pCMV-lacZ and the indicated expresssion plasmids. For each experiment (n = 6), values obtained for cells transfected 
with the luciferase reporter alone were set to 1. *** p < 0.001 as determined by student's t-test compared to all other col-
umns; n.s. not significant. (B) HER911 cells were co-transfected with pSCT1-HA-Clock and pSCT1-Per2. Total cell extracts (left 
panel) or immunoprecipitates using an anti-HA antibody (right panel) were subjected to Western blotting using an antibody 
against PER2. Blots are representative results from one experiment, the co-immunoprecipitation was repeated twice. WB 
Western Blot, IP immunoprecipitation.Page 4 of 16
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tested (Fig. 3B). Additional co-transfection of Clock had
no effect on GAL4-BMAL1 levels. PER2-VP16 expression
levels were slightly elevated when Clock, but not Cry, was
co-transfected whereas no further increase was seen with
Clock in the presence of Cry (Fig. 3C).
CRY1 and CRY2 have different effects on PER2-BMAL1 interactionFigure 3
CRY1 and CRY2 have different effects on PER2-BMAL1 interaction. (A) HER911 cells were co-transfected with pFR-
luc, pCMV-lacZ, pSCT1-Per2-VP16, pSCT1-Gal4-Bmal1 and the indicated doses of pSTC-TK-Cry1/2 with or without addition of 0.3 
μg pSCT1-Clock. For each experiment (n = 3), values obtained for cells transfected with pSCT1-Clock but without pSTC-TK-Cry 
were set to 1. (B), (C) and (D) HER911 cells were co-transfected with pSCT1-Per2-VP16, pSCT1-Gal4-Bmal1, pEGFP-N3 and 
0.001, 0.01, 0.1 or 1 μg pSTC-TK-Cry1/2 (B) or 0.1 μg pSTC-TK-Cry1/2 with and without addition of 0.3 μg pSCT1-Clock (C, D). 
The amount of PER2-VP16, GAL4-BMAL1 and GFP was determined by Western blotting of total lysates (B, C) or nuclear and 
cytoplasmic fractions (D). Antibodies against CREB and HSP90 were used to verify correct cell fractionation. PER2-VP16 and 
GAL4-BMAL1 were normalized to GFP to correct for transfection efficiency. For both proteins, values obtained for cells trans-
fected with pSCT1-Per2-VP16, pSCT1-Gal4-Bmal1 and pEGFP-N3 only were set to 1 for each experiment (n = 4 for B and D, n = 
5 for C). Blots are representative results from one experiment.Page 5 of 16
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PER1/2 has been reported [7]. It has also been described
that CRY expression has an effect on BMAL1 localization
[14]. Since in the mammalian two-hybrid system used in
this study only fusion proteins that are present in the
nucleus can activate the transcription of the reporter, we
determined the subcellular localization of GAL4-BMAL1
and PER2-VP16. To this end, we performed Western blots
on nuclear and cytoplasmic fractions of HER911 cells
transfected as described above (Fig. 3D). The effects of
Cry1/2 and Clock basically followed the pattern observed
in total extracts for both fractions, we did not detect any
gross redistributions of the fusion proteins. If anything,
the influence was stronger in the cytoplasm, which would
not influence mammalian two-hybrid results.
In summary, fusion protein expression levels do not cor-
relate with the degree of reporter activation, since e.g. the
highest amount of Cry1 leads to a marked increase in
PER2-VP16 expression and nonetheless significantly
decreases luciferase activity. We therefore conclude that
the modulations of luciferase activity we observe in the
mammalian two-hybrid system reflect true modulations
of PER2-BMAL1 interaction by the respective co-expressed
proteins. In this scenario, CLOCK would strengthen the
interaction because the increase in luciferase activity
caused by co-transfection of Clock (Fig. 3A) is markedly
higher than the slight increase in PER2-VP16 expression.
A similar effect has in fact been observed by Kiyohara et al.
for the interaction of CRY1 with the heterodimer [15].
Given that in our system, PER2 interacts with both BMAL1
and CLOCK (and those two in turn with each other), a sta-
bilization of PER2-BMAL1 interactions by CLOCK might
be envisaged through the formation of a heterotrimer
where each component interacts with the other two. The
increase in PER2-VP16 expression after co-transfection of
Cry1 is very likely due to a stabilization of PER2-VP16 by
CRY1, an effect that has been reported before [18,25,26].
CRY1 appears to be more effective than CRY2 in disrupt-
ing PER2-BMAL1 interactions. The observed decrease in
luciferase activity is not due to less PER2-VP16 or GAL4-
BMAL1 available, on the contrary, there is clearly elevated
PER2-VP16 expression. For Cry2, a less pronounced
increase in expression is observed, especially with low
amounts of co-transfected Cry2, which, however, already
cause a marked increase in reporter activation. Of course,
these effects might be cell-specific; however, they fit in
with previous observations. Recently, CRY1 has been pro-
posed as the main repressor of BMAL1-CLOCK-mediated
transcription [15,24], and previous studies in mice also
show that the Cry1 gene has a dominant role over Cry2,
because one normal Cry1 allele sustains normal circadian
rhythms in behavior, while one Cry2 allele leads to
arrhythmicity [20]. Since the PER proteins have been
reported to be weaker repressors than CRY1/2 [7,27], the
ability of CRY1 (and, to a lesser extent, CRY2) to disrupt
PER2-BMAL1 interactions might be important to allow
stronger repression of the transcription activation poten-
tial of the heterodimer.
PER2 does not significantly affect the interaction between 
CRY and BMAL1
If the CRY proteins, especially CRY1, act as the main
repressors, PER2 should not be able to destabilize the
interactions between the CRY proteins and BMAL1. Pre-
liminary experiments showed that co-transfection of
small amounts of Per2 indeed did not reduce CRY1/2-
BMAL1-mediated luciferase activation in the mammalian
two-hybrid system (data not shown). To further test this
hypothesis, we co-transfected Cry1/2-VP16 together with
Gal4-Bmal1 and an excess of Per2. Since the DNA amount
that can be transfected is limited, we decreased the
amounts of co-transfected Cry1/2-VP16 rather than
increased that of Per2. For Cry1 (Fig. 4A) as well as for
Cry2 (Fig. 4B) we found a dose-dependent reduction in
luciferase activity as co-transfected plasmid amount
decreased, both in the presence (solid circles) and the
absence (open circles) of PER2. Co-transfection of Per2
actually increased luciferase activity instead of diminish-
ing it, which might hint at a stabilization of CRY-BMAL1
interactions by PER2. Alternatively, it could be due to
increased protein expression or nuclear availability of the
fusion proteins; we were, however, not able to determine
expression levels of the fusion proteins in this experimen-
tal set-up. The currently transfected amounts of Cry1/2-
VP16 were too low to yield any signal in a Western blot,
and we were not able to increase them in a way that would
allow a detection of the lowest amount without exceeding
the transfection limit with the highest amount, which is
50-fold higher. We tried to at least assess the influence of
co-transfection of Per2 on the expression levels of GAL4-
BMAL1 and CRY1/2-VP16 using only one amount of each
expression plasmid. PER2 co-expression did not affect
CRY1/2-VP16 levels and had only a small effect on GAL4-
BMAL1 expression, which was slightly decreased (Fig. 4C
and 4D). Consequently, the increase in luciferase activity
observed when Per2 is co-transfected very likely is not due
to elevated fusion protein levels.
Although in our system, we could not detect any interac-
tion between CRY1 and CLOCK, it has been described in
other systems, indicating that CLOCK might have an
impact on CRY1-BMAL1 interaction. Indeed, when we co-
transfected increasing amounts of Clock expression plas-
mid together with Gal4-Bmal1 and Cry1-VP16, we
observed a dose-dependent increase in luciferase activity
(Fig. 4E) whereas GAL4-BMAL1 and CRY1-VP16 expres-
sion levels remained almost constant (Fig. 4F). CLOCK
thus appears to stabilize the interaction, possibly byPage 6 of 16
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Influence of PER2 and CLOCK on CRY1/2-BMAL1 interactionsFigure 4
Influence of PER2 and CLOCK on CRY1/2-BMAL1 interactions. (A) and (B) HER911 cells were co-transfected with 
pFR-luc, pCMV-lacZ, pSCT1-Gal4-Bmal1 and 2 μg pSCT1-Per2. To obtain the indicated fold excess of pSCT1-Per2, 0.1, 0.04, 0.02, 
0.01, 0.004 and 0.002 μg pSCT1-Cry1-VP16 (A) or pSCT1-Cry2-VP16 (B) were co-transfected (solid circles). Each dose of pSCT1-
Cry1/2-VP16 was also transfected in the absence of pSCT1-Per2 (open circles) to assess the effect of PER2 on CRY1/2-BMAL1 
interactions. For each experiment (n = 3), values obtained for cells transfected with the highest amount of pSCT1-Cry1/2-VP16 
but without pSCT1-Per2 were set to 1. Note that the amounts pSCT1-Cry1/2-VP16 transfected are reversely plotted on the X 
axis, so that fold excess pSCT1-Per2 increases from left to right (see numbers below the graphs). (C), (D) and (F) HER911 cells 
were co-transfected with pSCT1-Gal4-Bmal1, pEGFP-N3 and either pSCT1-Cry1-VP16 (C and F) or pSCT1-Cry2-VP16 (D). For (C) 
and (D), transfections were performed with or without 2 μg pSCT1-Per2, for (F) 0.1, 0.3 or 1 μg pSCT1-Clock were co-trans-
fected. The amount of CRY1/2-VP16, GAL4-BMAL1 and GFP was determined by Western blotting of total lysates. CRY1/2-
VP16 and GAL4-BMAL1 were normalized to GFP to correct for transfection efficiency. For all proteins, values obtained for 
cells transfected with pSCT1-Cry1/2-VP16, pSCT1-Gal4-Bmal1 and pEGFP-N3 only were set to 1 for each experiment (n = 3). 
Blots are representative results from one experiment. (E) HER911 cells were co-transfected with pFR-luc, pCMV-lacZ, pSCT1-
Gal4-Bmal1, pSCT1-Cry1-VP16 and the indicated amounts of pSCT1-Clock. For each experiment (n = 3), values obtained for cells 
transfected with pSCT1-Gal4-Bmal1 and pSCT1-Cry1-VP16 only were set to 1.
BMC Molecular Biology 2008, 9:41 http://www.biomedcentral.com/1471-2199/9/41inducing conformational changes in BMAL1 that facilitate
CRY1 binding. As for PER2, a heterotrimer might be
formed that is more stable than the CRY1-BMAL1 com-
plex alone, even in the absence of direct CRY1-CLOCK
interactions. The results of Kiyohara et al. [15] support a
heterotrimer formation as well, since they co-immuno-
precipitate CRY1 with CLOCK only in the presence of
BMAL1.
Lee et al. report impaired nuclear translocation of CRY
proteins in the livers of Per1/Per2 double mutant mice
[19], and it has been demonstrated that PER2 lacking the
nuclear localization signal can retain CRY proteins in the
cytoplasm [28]. However, overexpressed CRY1 and 2 have
been shown to be nuclear proteins in cells [7]. Co-trans-
fection of (full-length) Per2 should therefore in principle
not influence the sub-cellular localization of at least the
CRY proteins. To our knowledge, no dependence of sub-
cellular localization of BMAL1 on PER2 has been
reported, either, and since BMAL1 is a predominantly
nuclear protein [19], its nuclear availability should not
drastically vary. Thus, we did not perform any cell frac-
tionations for CRY1/2-VP16 and GAL4-BMAL1.
PER2, CRY1 and CRY2 bind different domains of BMAL1
To map the regions of the BMAL1 protein that are critical
for interactions with CRY1/2 and PER2 we constructed
three deletion mutants of Bmal1 fused to the Gal4 DBD
(Gal4-Bmal1ΔHLH/PAS A; Gal4-Bmal1ΔPAS B/C-term and
Gal4-Bmal1ΔC-term). We confirmed that their expression
levels were comparable to those of full-length GAL4-
BMAL1 (data not shown) and tested their capacity to acti-
vate the luciferase reporter in the mammalian two-hybrid
system when co-expressed together with PER2-VP16,
CRY1-VP16 or CRY2-VP16, respectively.
Co-transfection of Gal4-Bmal1ΔC-term with Per2-VP16 led
to a strong increase in luciferase activity (150-fold that of
the reporter alone), indicating that the C-terminus of
BMAL1 is not essential for PER2 binding. Cry1-VP16 was
also able to augment luciferase activity significantly above
background; however, the effect was not as strong as that
observed with Per2-VP16 (50-fold). No significant
increase was observed for Cry2-VP16. We therefore con-
clude that CRY1 is still able to weakly interact with this
truncated version of BMAL1, whereas CRY2 binding is
completely abolished (Fig. 5B).
When we tested Gal4-Bmal1ΔPAS B/C-term, a deletion
mutant lacking not only the C-terminus but also the PAS
B domain, only co-transfection with Per2-VP16 led to a
slight (5-fold) elevation in luciferase activity. Neither
Cry1-VP16 nor Cry2-VP16 had any statistically significant
effect (Fig. 5C). PER2 consequently still appears to be able
to bind to this BMAL1-mutant, although to a much lesser
extent than to GAL4-BMAL1ΔC-term, which indicates that
the PAS domain of BMAL1 might be involved in PER2
binding. It also seems to play a role in CRY1 binding since
the residual reporter transactivation observed with GAL4-
BMAL1ΔC-term and CRY1-VP16 disappears when the
deletion in Bmal1 is extended to the PAS B domain.
GAL4-BMAL1ΔHLH/PAS A was able to activate the luci-
ferase reporter to a considerable extent already in the
absence of any VP16 fusion protein. Co-transfection with
all three VP16 fusion constructs thus caused only slight,
but nonetheless significant, increases in luciferase activity
(1.5-fold for Per2-VP16, 2.5-fold for Cry1-VP16 and 3-fold
for Cry2-VP16 as compared to Gal4-Bmal1ΔHLH/PAS A
alone; Fig. 5D). Although it is difficult to draw any conclu-
sions due to the high background activity of this Bmal1
mutant, these results confirm the observations made
using the other two truncated forms, namely that the N-
terminal portion of BMAL1 appears to be most important
for PER2 binding, less crucial for the binding of CRY1 and
not essential for interactions with CRY2.
In summary, our interaction data leads to a model where
PER2 binds to the N-terminus of BMAL1, where the PAS A
domain is located. Since PER2 itself also contains a PAS
domain, a direct interaction between these two domains
could be envisaged. CRY1 would bind more towards the
PAS B domain and CRY2 even further C-terminally. This
hypothesis is in line with observations of Kiyohara et al.
[15] who report normal binding of PER2, but not of
CRY1, to a C-terminally truncated version of BMAL1. Oth-
ers have also identified mutations in the C-terminus of
BMAL1 that weaken BMAL1-CRY1 interactions [24]. To
our knowledge, the binding site for CRY2 has not been
mapped in BMAL1 so far. However, given that CRY2 was
less effective than CRY1 in disrupting PER2-BMAL1 inter-
actions in our system, it can be expected to be further away
than the binding site for CRY1, which, in our model,
would actually be the case.
CBP and p300, transcriptional co-activators found to
interact with BMAL1, have also been hypothesized to bind
to the extreme C-terminus that harbors a putative tran-
scription activation domain [13]. Thus, the fact that CRY1
and CRY2 bind more C-terminally to BMAL1 than PER2
might also explain why they have a stronger capacity to
inhibit BMAL1-CLOCK-mediated transcriptional activa-
tion.
Confirmation of the interactions in cos-7 cells
We were not able to confirm the interactions identified in
the mammalian two-hybrid system by co-immunoprecip-
itation of in vitro transcribed/translated proteins (data not
shown). This might be due either to the presence of bridg-
ing proteins in HER911 cells or to post-translational mod-Page 8 of 16
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Mapping of PER2, CRY1 and CRY2 binding sites in BMAL1Figure 5
Mapping of PER2, CRY1 and CRY2 binding sites in BMAL1. HER911 cells were co-transfected with pFR-luc and μg 
pCMV-lacZ together with the indicated expresssion plasmids. For each experiment (n = 5–7), values obtained for cells trans-
fected with the luciferase reporter alone were set to 1. Significant luciferase reporter activation by pSCT1-Per2/Cry1/Cry2-VP16 
as compared to the respective pSCT1-Gal4-Bmal1 construct alone was determined by student's t-test (* p < 0.05, ** p < 0.01, 
*** p < 0.001).
BMC Molecular Biology 2008, 9:41 http://www.biomedcentral.com/1471-2199/9/41ifications of the interaction partners, which are vital for
circadian clock function in vivo [19]. We tried to precipi-
tate one in vitro expressed interaction partner together
with one expressed in HER911 cells in order to reconsti-
tute potential post-translational modifications on at least
one of the proteins. However, in our hands, this was not
possible either (data not shown), indicating that modifi-
cations of both partners might be necessary for interac-
tions.
As the primary interaction partners of clock components
are other clock components, we wanted to find out
whether clock genes, whose products might act as bridg-
ing proteins, were endogenously expressed in HER911
cells. We performed RT-PCR for hPer1, hPer2, hBmal1,
hClock, hCry1 and hCry2 and were indeed able to detect
transcripts of all six genes (Fig. 6). We did not detect any
expression on the protein level, however (data not
shown). Still, this does not necessarily mean that they are
truly absent because their levels might just be below the
detection limit. Consequently, it cannot be excluded that
endogenous oscillator components are present and con-
tribute to the interactions observed in HER911 cells. We
therefore tried to reproduce our results in cos-7 cells that
have been reported to express hardly any endogenous
clock genes [29].
We performed the mammalian two-hybrid assay as
described above to identify interactions of PER2-VP16,
CRY1-VP16 and CRY2-VP16 with GAL4-BMAL1 and
GAL4-CLOCK, respectively. As in HER911 cells, all three
VP16 fusions were able to significantly increase luciferase
activity when co-transfected with Gal4-Bmal1 (200-fold
for Per2-VP16, 110-fold for Cry1-VP16 and 70-fold for
Cry2-VP16 as compared to the reporter alone). This incre-
ment was not observed when they were co-expressed with
the Gal4 DBD or when Gal4-Bmal1 was co-transfected
with VP16 (Fig. 7A). Thus, PER2, CRY1 and CRY2 interact
with BMAL1 also in cos-7 cells.
GAL4-CLOCK activated the reporter to such a high extent
already in the absence of interaction partners that no fur-
ther significant increase in luciferase activity could be
detected upon co-expression of PER2-VP16, CRY1-VP16
or CRY2-VP16 (Fig. 7B).
HER911 cells express endogenous clock genes on the mRNA levelFigure 6
HER911 cells express endogenous clock genes on the mRNA level. cDNA of HER911 cells was obtained by reverse 
transcription of total RNA. hPer1, hPer2, hCry1, hCry2, hBmal1 and hClock cDNAs were amplified by PCR (lanes c). As positive 
control and to distinguish between true cDNA products (black arrowheads) and products from contaminating genomic DNA 
(gray arrowheads), a parallel reaction was run using human genomic DNA as template (lanes g). A negative control was done 
with water (lanes n).Page 10 of 16
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Confirmation of the interactions in cos-7 cellsFigure 7
Confirmation of the interactions in cos-7 cells. cos-7 (A-C, E) and HER911 (D, F) cells were co-transfected with pFR-luc, 
pCMV-lacZ and the indicated expression plasmids. For each experiment (n = 3 for A and B, n = 6 for C-F), values obtained for 
cells transfected with the luciferase reporter alone were set to 1. * p < 0.05, ** p < 0.01, *** p < 0.001 as determined by stu-
dent's t-test compared to the relevant controls (Gal4 fusion alone, Gal4 fusion and pSCT1-VP16, VP16 fusion and pFC-Gal4); n.s. 
not significant.
BMC Molecular Biology 2008, 9:41 http://www.biomedcentral.com/1471-2199/9/41To be able to analyze interactions with CLOCK, we con-
structed plasmids that encoded fusions of the GAL4 DBD
to PER2, CRY1 and CRY2 and a fusion of VP16 to CLOCK
and repeated the two-hybrid assay. Neither one of the
GAL4 DBD fusion proteins caused a more than 10-fold
increase in luciferase activity as compared to the reporter
alone. When Clock-VP16 was co-transfected, significantly
enhanced (55-fold) activity values were only observed for
Gal4-Per2, indicating that indeed only PER2 interacts
directly with CLOCK. Co-transfection of Gal4-Cry1 with
Clock-VP16 also led to higher luciferase values; however,
there were considerable inter-experimental variations,
and moreover, luciferase activity was already elevated
when VP16 alone was co-transfected. This hints at an
interaction between CRY1 and VP16 rather than between
CRY1 and CLOCK. The difference in luciferase activity
between co-transfection of Clock-VP16 and VP16 was not
statistically significant (Fig. 7C).
We wished to confirm the results obtained using the new
plasmids in HER911 cells and performed the same two-
hybrid assay as in cos-7 cells. In this cell line, however, all
three GAL4 DBD fusion proteins in combination with
CLOCK-VP16 significantly augmented reporter activity
levels (110-fold for GAL4-PER2, 190-fold for GAL4-CRY1
and 30-fold for GAL4-CRY2 as compared to the reporter
alone; Fig. 7D).
Since the interaction between CRY2 and CLOCK can only
be observed in HER911 cells, and only when using GAL4-
CRY2 and CLOCK-VP16 but not with GAL4-CLOCK and
CRY2-VP16 (Fig. 2D), we think that it might actually be
an artefact arising from an interaction of CRY2 with
endogenous PER2 and/or BMAL1 that, in turn, interacts
with CLOCK-VP16. Since for CRY1 and CLOCK, the
results were not quite clear in cos-7 cells, either, we co-
transfected HER911 cells with Cry1 and HA-Clock and
tried to co-immunoprecipitate CRY1 with an anti-HA
antibody, which did not work, however (data not shown).
We therefore believe that also this alleged direct interac-
tion is rather indirect and mediated by endogenous PER2
and/or BMAL1.
Co-transfection of the newly generated Gal4 fusion con-
structs with Bmal1-VP16 confirmed the results obtained
previously both in HER911 and in cos-7 cells. All three
proteins, GAL4-PER2, GAL4-CRY1 and GAL4-CRY2,
caused a significant increased in luciferase activity when
co-expressed together with BMAL1-VP16 (cos-7: 2900-
fold for GAL4-PER2, 450-fold for GAL4-CRY1 and 125-
fold for GAL4-CRY2, Fig. 7E; HER91: 110-fold for GAL4-
PER2, 70-fold for GAL4-CRY1 and 10-fold for GAL4-
CRY2, Fig. 7F).
In summary, our two-hybrid assays in cos-7 cells confirm
the interactions identified using the same system in
HER911 cells, namely PER2-BMAL1, PER2-CLOCK,
CRY1-BMAL1 and CRY2-BMAL1. We still cannot exclude
the involvement of endogenous bridging proteins that are
present in both cell lines. However, the fact that the inter-
actions still take place in a cell line devoid of endogenous
clock genes strongly argues against the notion that endog-
enous clock components are necessary to stabilize the
observed interactions.
Conclusion
In the present study we identify interactions between
BMAL1 and CLOCK, the two components of the positive
feedback loop of the mammalian circadian clock, and the
repressors PER2, CRY1 and CRY2. We show that PER2
binds to both BMAL1 and CLOCK whereas in our system,
CRY1 and CRY2 are only able to bind to BMAL1. These
interactions can be observed in transfected cells also in the
absence of endogenous clock proteins, but not in vitro,
indicating that post-translational modifications of the
interaction partners and/or not clock-related bridging
proteins are necessary to stabilize them. Analysis of dele-
tion mutants of BMAL1 reveals that PER2 interacts with
N-terminal regions, in contrast to CRY1 and CRY2 that
both need C-terminal motifs to be able to bind to BMAL1
(Fig. 8). The CRY proteins moreover seem to have a higher
affinity to BMAL1 than PER2. Taken together, our results
provide new insights into the interactions between acti-
vating and repressing components of the circadian clock.
They also confirm the notion that the CRY proteins are
more potent inhibitors of BMAL1-CLOCK mediated tran-
scriptional activation than the PER proteins, which might
be due both to their higher affinity to BMAL1 and their
binding to the C-terminus of BMAL1.
Methods
Plasmids
Full-length mouse cDNAs encoding BMAL1
[EMBL:BC011080], CLOCK [EMBL:AF000998], and PER2
[EMBL:AF036893] were cloned into pSCT1, a pUC18-
based expression vector carrying the CMV promoter and
intron 2, exon 3, and the 3' UTR of the β-globin gene to
enhance expression [30]. The fusion constructs for
BMAL1-GFP, GAL4-BMAL1, GAL4-CLOCK, GAL4-PER2,
GAL4-CRY1, GAL4-CRY2, CLOCK-VP16, PER2-VP16,
CRY1-VP16, CRY2-VP16, PAX5-VP15 and the VP16 tag
alone were expressed from the same vector. pSCT1 was
also used to express full-length bacterial β-galactosidase
and chloramphenicol acetyl transferase [31]; these con-
structs will be referred to as pCMV-lacZ and pCMV-CAT,
respectively.
To construct the Bmal1 deletions fused to Gal4, a 1051 bp
HindIII-BamHI fragment was excised from pSCT1-Gal4-Page 12 of 16
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278 of the full-length protein). Excision of a 1912 bp
BsrFI-HindIII fragment from the same vector gave rise to
pSCT1-Gal4-Bma1lΔHLHΔPAS A (aa 276–625), and a 488
bp SphI-BamHI fragment was excised to construct pSCT1-
Gal4-Bmal1ΔC-term (aa 1–467).
For the expression of CRY1 [EMBL:AF156986] and CRY2
[EMBL:AF156987], the respective full-length mouse
cDNAs were cloned into pSTC-TK, an expression vector
similar to pSCT1, which additionally contains a thymi-
dine kinase leader sequence after the CMV promoter. This
vector was also used to express HA-CLOCK.
GFP was expressed from pEGFP-N3 (Clontech, Saint-Ger-
main-en-Laye, France). The Gal4 DNA binding domain
was expressed from a modified version of pFA-CMV (Strat-
agene, Amsterdam, The Netherlands), which will be
referred to as pFC-Gal4. pFR-luc (Stratagene, Amsterdam,
The Netherlands) is a GAL4-based luciferase reporter vec-
tor containing the luciferase gene under the control of a
promoter with 5 GAL4 binding sites.
Cell culture and maintenance
HER911 human retinoblastoma cells [32] and cos-7 Afri-
can green monkey kidney cells [33] were routinely cul-
tured in DMEM High Glucose supplemented with 10%
FCS, 2 mM L-glutamine, and 100 U/ml penicillin/strepto-
mycin (all from Bioconcept, Allschwil, Switzerland) at
37°C in a humidified atmosphere containing 5% CO2
and split when confluent.
Reporter gene assays
Cells were seeded in 5 cm dishes, grown to 70% conflu-
ency and transfected with the calcium phosphate co-pre-
cipitation method. All transfection mixtures excluding
those for mock transfections contained 3 μg pFR-luc, 0.1
μg pCMV-lacZ to allow normalization of the luciferase
activity values. Unless indicated otherwise, 0.1 μg were
transfected for pSCT1-Gal4-Bmal1 and its deletion
mutants, pSCT1-Cry1/2-VP16, pSCT1-Gal4-Per2, pSCT1-
Clock-VP16, pSCT1-Bmal1-VP16, 0.3 μg for pSCT1-Gal4-
Clock and 0.5 μg for pSCT1-Per2-VP16. For pFC-Gal4,
pSCT1-VP16 and pSCT1-Pax5-VP16, an amount corre-
sponding to that of the respective Gal4 or VP16 fusion
construct tested was used.pCMV-CAT was used to obtain
the same amount of CMV promoter/enhancer in all sam-
ples. The total DNA amount was brought to 10 μg with
calf thymus DNA. The volume was brought to 125 μl, 125
μl 0.5 M CaCl2 in 0.1 M Hepes, pH 7.0 were added, and
samples were mixed well. After addition of 250 μl 0.75
mM Na2HPO4/0.75 mM NaH2PO4/.28 M NaCl in 0.05 M
Hepes, pH 7.0, samples were mixed again and incubated
for 1 minute at room temperature before adding the trans-
fection mixture to the cells. Cells were incubated over-
night, washed twice with TBS, supplied with fresh
medium, incubated for another 24 h and subsequently
lysed in 10% glycerol/10 mM MgAc/0.2% Triton X-100 in
50 mM Tris-HCl, pH 8.0.
Luciferase activity was measured according to [34]. 10 μl
lysate were added to 100 μl 1 mM ATP (Sigma, Buchs,
Switzerland)/10 mM MgAc/0.1 mg/ml BSA in 250 mM
Tris-HCl, pH 7.5. Samples were injected with 100 μl 200
μg coenzyme A/30 μg luciferine (both Sigma, Buchs, Swit-
zerland)/ml in 12.5 mM PIPES, pH 6.5 and light emission
was measured after a delay of 0.3 seconds during a 10 sec-
ond interval in a MicroLumatPlus luminometer (Berthold
Technologies, Bad Wildbach, Germany).
β-galactosidase activity was measured as described in [35].
10 μl lysate diluted 1:10 in lysis buffer were incubated
Model of PER2, CRY1 and CRY2 binding to BMAL1Figure 8
Model of PER2, CRY1 and CRY2 binding to BMAL1. Proposed binding sites for PER2, CRY1 and CRY2 in the BMAL1 
protein based on the interaction data shown in Fig. 5. Note that CRY1 and 2 bind closer to the C-terminus, which has been 
described as a potential interaction site for the activators CBP/p300 (see text).Page 13 of 16
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DMF in 90 mM Na3PO4/18 mM MgCl2, pH 8.0 for 20
minutes at 37°C protected from light. The reaction was
stopped by addition of 100 μl 120 mM glycine/6 mM
EDTA, pH 11.5, and the fluorescence of the samples was
measured at 360 nm excitation and 460 nm emission
wave length in a Lambda Fluoro 320 fluorimeter (MWG
Biotech, Ebersberg, Germany).
For statistical analysis, values obtained for mock-trans-
fected cells were subtracted from all other values. Subse-
quently, luciferase activity was normalized to β-
galactosidase activity to correct for transfection efficiency.
All experiments were performed at least three times, sam-
ples were measured in duplicates.
Preparation of total, nuclear and cytoplasmic extracts
Cells were seeded in 5 cm dishes for total extracts or in 10
cm dishes for IPs and fractionations, grown to 70% con-
fluency and transfected with linear polyethylenimine of
25 kDa (LINPEI25, Polysciences Europe, Eppelheim, Ger-
many). Again, pCMV-CAT was used to obtain equal
amounts of CMV promoter in each sample. For IPs, 10 μg
pSCT1-Bmal1-GFP and pSCT1-HA-Clock and 5 μg pSCT1-
Per2, pSTC-TK-Cry1 and pSTC-TK-Cry2 were transfected.
For fractionations and total extracts that were not used for
IPs, 1 μg pSCT1-Per2-VP16, 3 μg pSCT1-Cry1/2-VP16 and
0.5 μg pSCT1-Gal4-Bmal1 were used for 5 cm dishes; for
10 cm dishes, amounts were increased 3-fold. 0.2 μg
pEGFP-N3 were included in each transfection to control
transfection efficiency and to allow normalization of
expression levels. Plasmid DNA was brought to 200 μl
with 150 mM NaCl in 20 mM HEPES pH 7.4 and mixed
with 13 equivalents of LINPEI25. Samples were incubated
for 10 minutes at room temperature before adding the
DNA-LINPEI25 complexes directly to the culture
medium. After 6 hours cells were washed once with TBS,
supplied with fresh medium and incubated for another 24
hours before lysis.
For total extracts, cells were lysed in 1 mM EDTA/150 mM
NaCl/1% Triton X-100/10% glycerol/0.05% β-mercap-
toethanol/protease inhibitor cocktail (complete EDTA-
free; Roche, Rotkreuz, Switzerland) in 20 mM Tris-HCl,
pH 7.5.
Nuclear and cytoplasmic fractions were obtained accord-
ing to [36]. Cells were incubated in 10 mM KCl/1.5 mM
MgCl2/0.5 mM DTT/protease inhibitor cocktail in 10 mM
HEPES-KOH, pH 7.9 for 15 minutes on ice. After centrif-
ugation for 5 minutes at 1200 g and 4°C, the supernatant
was stored as the cytosolic fraction. The pellet was washed
twice with the same buffer and resuspended in 25% glyc-
erol/0.42 M NaCl/1.5 mM MgCl2/0.2 mM EDTA/0.5 mM
DTT/protease inhibitor cocktail in 20 mM Hepes-KOH,
pH 7.9. Samples were incubated in rotation for 20 min-
utes at 4°C and centrifuged for 15 minutes at 13000 g and
4°C. The supernatant was stored as the nuclear fraction.
Protein concentration of total extracts or fractions was
determined using the BioRad Protein Assay (BioRad,
Reinach, Switzerland) according to manufacturer's
instructions. 4× loading dye (4% SDS/4% β-mercaptoeth-
anol/40% glycerol in 200 mM Tris-HCl, pH 6.8) was
added to all samples and they were boiled before subjec-
tion to SDS-PAGE.
Co-immunoprecipitation
Cells were transfected with linear polyethylenimine of 25
kDa as described above. For co-immunoprecipitations
with BMAL1-GFP, 600 μg total protein were brought to a
final volume of 800 μl with lysis buffer and incubated
with 2 μg Anti-GFP antibody (Roche, Rotkreuz, Switzer-
land) and 50 μl protein G agarose beads (Roche,
Rotkreuz, Switzerland) in rotation over night at 4°C.
Beads were washed twice with lysis buffer and once with
250 mM NaCl/10% glycerol/0.1% NP-40 in 50 mM Tris-
HCl, pH 7.5.
For co-immunoprecipitations with HA-CLOCK, 600 μg
total protein were incubated with 0.5 μg anti-HA high
affinity antibody (Roche, Rotkreuz, Switzerland) in rota-
tion over night at 4°C. 50 μl protein G agarose beads were
added and samples were incubated for another 3 hours at
4°C. Beads were washed three times using 0.1 mM EDTA/
10% glycerol/1% Triton-X 100/0.3% β-mercaptoethanol
in 30 mM Tris-HCl, pH 7.5 supplemented with 1 M, 0.1
M and no NaCl, respectively. In both cases, beads were
resuspended in 2% SDS/2% β-mercaptoethanol/20%
glycerol in 100 mM Tris-HCl, pH 6.8. Samples were
boiled and subsequently subjected to SDS-PAGE.
Western blot
Total lysates, cellular fractions or immunoprecipitates
were separated by SDS-PAGE and transferred onto nitro-
cellulose membranes. Membranes were blocked for 1 h at
room temperature in 5% milk/0.1% Tween-20 in TBS for
PER2, CRY1, CRY2, GFP and BMAL1 and in 1% milk/
0.1% Tween-20 in TBS for HA and incubated with primary
antibodies diluted in blocking buffer at 4°C over night.
Antibodies and dilution were anti-PER2 1:1000 (BD Bio-
sciences, Allschwil, Switzerland for total lysates and
immunoprecipitations; gift from J. Ripperger and S.
Brown for fractions [8]), anti-BMAL1 1:1000 (gift from J.
Ripperger and S. Brown [8]), anti-CRY1 1:500, anti-CRY2
1:750 (both Alpha Diagnostics, San Antonio, USA), anti-
GFP 1:3000, anti-HA 1:1000 (both Roche, Rotkreuz, Swit-
zerland). Membranes were washed and incubated with
appropriate HRP-conjugated secondary antibodies (anti-
rabbit, anti-mouse and anti-rat; all Sigma, Buchs, Switzer-Page 14 of 16
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formed using the Western blotting detection reagents kit
(Amersham Biosciences, Freiburg, Germany) according to
manufacturer's instructions. Membranes were exposed on
Hyperfilm (Amersham Biosciences, Freiburg, Germany).
RT-PCR
HER911 cells were seeded in 10 cm dishes and grown to
80% confluency. Cells were washed once with TBS and
lysed in 1 ml RNA bee (AMS Biotechnology, Abingdon,
UK) directly in the dish. Total RNA was isolated according
to manufacturer's instructions and RNA integrity was
checked on an agarose gel. cDNA was synthesized from 2
μg total RNA using SuperScript II (Invitrogen, Basel, Swit-
zerland) according to manufacturer's instructions.
Human genomic DNA (for primer optimization and as
positive control) was from Promega (Wallisellen, Switzer-
land).
Primers for the amplification of human clock genes were
5'-CCCACCCCACCAGCCACTAC-3' and 5'-CCTGT-
GCCGGAGCGCGAGTC-3' for hPer1 (GenBank
GeneID:5187), 5'-TGGATGTGGCTGTCTTGTAG-3' and
5'-GCCGGTGGATCTGCTCTGTG-3' for hPer2 (GenBank
GeneID:8864), 5'-TGGATGTGGCTGTCTTGTAG-3' and
5'-TTTGGCTACCTTTTGGATAC-3' for hCry1 (GenBank
GeneID:1407), 5'-AAGCGTTCCCCTCTCGATAC-3' and
5'-AGGGACAGATGCCAGTAGAC-3' for hCry2 (GenBank
GeneID:1408), 5'-CATTCCTTCCAGTGGCCTAC-3' and
5'-GTCAACAGGGCCACCCAGTC-3' for hBmal1
(hARNTL; GenBank GeneID:406) and 5'-TCATCG-
GCAACAAGAAGAAC-3' and 5'-GCTTCCGGCTGCAG-
GCTGAG-3' for hClock (GenBank GeneID:9575). All
primers were designed based on the genomic sequence so
that amplicons would contain an intron to distinguish
between products obtained from genomic and cDNA
(1003/562 bp for hPer1, 590/237 bp for hPer2, 412/188
bp for hCry1, 511/202 bp for hCry2, 1017/213 bp for
hBmal1, 2187/399 bp for hClock). 40 PCR cycles (30 sec-
onds denaturation at 95°C, 30 seconds annealing, 2 min-
utes elongation at 72°C) were run, annealing
temperatures were 62°C for hPer1, 60°C for hPer2,
hBmal1 and hClock, 56°C for hCry2 and 50°C for hCry1.
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